Aptose Biosciences (APTO) Stock Rating Lowered by ValuEngine
Aptose Biosciences (NASDAQ:APTO) (TSE:APS) was downgraded by equities research analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research note issued on Friday.
Other research analysts have also recently issued research reports about the company. Zacks Investment Research upgraded Aptose Biosciences from a “hold” rating to a “buy” rating and set a $2.00 price target for the company in a research note on Friday, November 17th. Canaccord Genuity set a $7.00 price target on Aptose Biosciences and gave the stock a “buy” rating in a research note on Wednesday, November 15th. HC Wainwright set a $4.00 price target on Aptose Biosciences and gave the stock a “buy” rating in a research note on Wednesday, November 15th. Finally, Roth Capital restated a “buy” rating and issued a $5.00 price target on shares of Aptose Biosciences in a research note on Monday, October 23rd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $4.50.
Aptose Biosciences (NASDAQ:APTO) traded down $0.02 during mid-day trading on Friday, hitting $2.01. The stock had a trading volume of 312,144 shares, compared to its average volume of 393,563. Aptose Biosciences has a 52-week low of $0.78 and a 52-week high of $2.30.
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
Receive News & Stock Ratings for Aptose Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc. and related stocks with our FREE daily email newsletter.